NASDAQ$OCGN
Ocugen Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Ocugen Inc reported Q2 2025 results showing collaborative arrangement revenue of $1.4 million and a net loss of $14.7 million.
The company recognized $1.4 million in collaborative arrangement revenue for the quarter. Operating expenses totaled $15.2 million, resulting in a loss from operations of $13.8 million and a net loss of $14.7 million or $0.05 per share. Cash and cash equivalents stood at $27.0 million at quarter end amid ongoing clinical development activities.
- Collaborative arrangement revenue increased to $1.373 million from $1.141 million in Q2 2024.
- Research and development expenses were $8.4 million and general and administrative expenses were $6.8 million.
- Net loss per share improved to $(0.05) from $(0.06) in the prior-year quarter.
- Company maintains going-concern qualification with $27.0 million cash and continued focus on Phase 3 trials for OCU400.
Headline financials
Revenue & EPS history
Ocugen · Revenue · Quarterly
$1.37M
Revenue by segment
Ocugen · $1.37M total across 1 segment · Q2 2025
- Collaborative Arrangement$1.37M—100.0%
Forward guidance
Company plans to complete OCU400 Phase 3 enrollment and target BLA/MAA filings in 2026 while advancing OCU410ST Phase 2/3 trial with BLA target in 2027.
Tailwinds
- Positive two-year OCU400 Phase 1/2 data across mutations
- EMA ATMP classification and centralized procedure eligibility for OCU400
- FDA clearance for OCU410ST Phase 2/3 pivotal trial
Headwinds
- Substantial doubt about ability to continue as going concern
- Need for significant additional capital to fund operations
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-1.2%
Avg return
Earnings day
-2.7%
Avg return
5 days after
-3.7%
Avg return
30 days after
42%
19 / 45 earnings
Positive
+31.5%
Q1 2016
Best reaction
-27.5%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -1.0% | +1.0% | -12.0% | |
| Q4 2025 | +5.4% | -10.8% | -3.8% | |
| Q3 2025 | -1.4% | -5.6% | -14.7% | |
| Q1 2025 | -2.3% | +0.9% | +53.8% | |
| Q4 2024 | -2.8% | -5.8% | +12.2% | |
| Q3 2024 | -0.9% | -11.3% | -19.4% | |
| Q2 2024 | +5.9% | +11.9% | -3.4% | |
| Q1 2024 | +8.3% | +5.5% | -16.0% | |
| Q4 2023 | -9.4% | -17.0% | +24.5% | |
| Q3 2023 | -6.3% | -2.6% | +1.3% | |
| Q2 2023 | -8.8% | +3.4% | -10.4% | |
| Q1 2023 | +3.3% | +7.3% | -32.1% | |
| Q4 2022 | +2.3% | +6.6% | -15.6% | |
| Q3 2022 | -3.3% | +15.7% | -8.5% | |
| Q2 2022 | +2.9% | +2.2% | -13.4% | |
| Q1 2022 | -12.3% | -19.7% | +0.4% | |
| Q4 2021 | +15.0% | +14.9% | +13.9% | |
| Q3 2021 | -11.4% | -8.4% | -41.3% | |
| Q2 2021 | +8.4% | +5.2% | -0.8% | |
| Q1 2021 | +6.2% | -10.1% | -9.0% | |
| Q4 2020 | -6.6% | -15.4% | -39.5% | |
| Q3 2020 | +1.4% | +3.8% | +8.0% | |
| Q2 2020 | -20.2% | -23.0% | -48.8% | |
| Q1 2020 | +0.0% | -5.2% | -24.2% | |
| Q4 2019 | -15.7% | -19.1% | -11.1% | |
| Q3 2019 | -27.5% | -50.6% | -64.7% | |
| Q2 2019 | +4.3% | -1.1% | +43.9% | |
| Q1 2019 | -4.7% | -8.8% | +54.9% | |
| Q4 2018 | -7.1% | -7.9% | +52.8% | |
| Q3 2018 | -4.7% | -17.8% | -9.3% | |
| Q2 2018 | +6.1% | +17.4% | -68.9% | |
| Q1 2018 | -2.3% | -17.3% | +7.3% | |
| Q4 2017 | -3.3% | -1.3% | -5.3% | |
| Q3 2017 | -5.2% | -9.8% | -9.9% | |
| Q2 2017 | +2.2% | -0.6% | +6.7% | |
| Q1 2017 | -1.2% | -1.2% | +0.0% | |
| Q4 2016 | +1.1% | -9.0% | +0.0% | |
| Q3 2016 | -3.7% | -9.4% | -23.8% | |
| Q2 2016 | +7.1% | +86.4% | +82.8% | |
| Q1 2016 | +31.5% | — | — | |
| Q4 2015 | +8.9% | — | — | |
| Q3 2015 | -16.6% | — | — | |
| Q2 2015 | +3.0% | — | — | |
| Q1 2015 | -2.5% | — | — | |
| Q4 2014 | +4.2% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro